SCHEMBL23675437

SCHEMBL23675437

O=C(NCc1ccc(F)cc1Cl)c1cc(Cl)ccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 4/20 0.56
TAS1R3 Q7RTX0 1/20 0.55
TAS1R1 Q7RTX1 1/20 0.55
TAS1R2 Q8TE23 1/20 0.55
TMPRSS4 Q9NRS4 1/20 0.55
CDK1 P06493 1/20 0.52
P2RX4 Q99571 1/20 0.52
P2RX7 Q99572 1/20 0.52
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.52
KMT2A Q03164 1/20 0.52
ERCC1 P07992 3/20 0.50
ERCC4 Q92889 3/20 0.50
LMNA P02545 3/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.48
NLRP1 Q9C000 1/20 0.48
TSHR P16473 1/20 0.48
EPHX2 P34913 1/20 0.48
ROCK2 O75116 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30100395 0.90 ERCC1 (0.59) P2RX1TMPRSS4CDK1P2RX4P2RX7
SCHEMBL23675382 0.90 ERCC1 (0.59) P2RX1TMPRSS4CDK1P2RX4P2RX7
SCHEMBL23675392 0.90 TAS1R3 (0.62) P2RX1TAS1R3TAS1R1TAS1R2TMPRSS4
SCHEMBL6357645 0.89 ALDH1A1 (0.53) P2RX7MEN1KMT2ALMNAMAPT
SCHEMBL23675403 0.84 EPHX2 (0.55) P2RX1TMPRSS4CDK1P2RX4P2RX7
SCHEMBL13812639 0.82 P2RX1 (0.66) P2RX1TAS1R3TAS1R1TAS1R2TMPRSS4
SCHEMBL23675419 0.80 NPC1 (0.65) P2RX1TMPRSS4P2RX4P2RX7MEN1
SCHEMBL13812915 0.80 P2RX1 (0.70) P2RX1TAS1R3TAS1R1TAS1R2TMPRSS4
SCHEMBL6357659 0.80 TP53 (0.56) P2RX7MEN1KMT2AROCK2ROCK1
SCHEMBL6357851 0.78 CNR1 (0.55) TAS1R3TAS1R1TAS1R2P2RX7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
EP-4093401-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING The Board of Regents of the University of Texas System (US) 2022-11-30 EP disclosed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE P2RX1 3088/4885TAS1R3 2667/4885TAS1R1 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.